With about 60 novel agents carrying user fee goal dates in the coming year, it is only to be expected that some diseases will have multiple novel candidates. Here are some of the top matchups to watch.
Ulcerative colitis therapies have benefited from the explosion in immunology-focused agents with wide-ranging uses, from the venerable TNF inhibitors to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?